Results 51 to 60 of about 453,809 (210)

An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins

Scientific Reports, 2021
Tuberculosis is one the oldest known affliction of mankind caused by the pathogen Mycobacterium tuberculosis. Till date, there is no absolute single treatment available to deal with the pathogen, which has acquired a great potential to develop drug ...
Rahul Sharma, Vikrant Singh Rajput, Salma Jamal, Abhinav Grover, Sonam Grover   +4 more
doaj   +1 more source

Ruta graveolens L. in Evidence‐Based Phytotherapy: Pharmacological Activities, Bioactive Compounds and Safety

Phytotherapy Research, EarlyView.
Graphical representation of ethnomedical uses, major bioactive compounds, pharmacological potential and toxicological risks of Ruta graveolens L. ABSTRACT Ruta graveolens L. is widely used in traditional European, Asian, African, and South American medicine for digestive, nervous, cardiovascular, respiratory, and reproductive disorders.
Tetiana Serhiienko, Victoriya Georgiyants, Liudas Ivanauskas, Olha Mykhailenko   +3 more
wiley   +1 more source

Comprehensive evaluation of metagenomic next‐generation sequencing for pathogen identification in patients with suspected infection: Establishment of a standardized validation workflow

VIEW, EarlyView.
Comprehensive evaluation of metagenomic next‐generation sequencing for pathogen identification in patients with suspected infection: Establishment of a standardized validation workflow. Abstract Metagenomic next‐generation sequencing (mNGS) enables unbiased identification of pathogens directly from clinical specimens. Despite its growing application in
Wen Shu, Qiaomei Guo, Han Yang, Huiqin Jiang, Chunyan He, Xueqing Wang, Yuting Fang, Yue Yin, Liwen Zhong, Zhijing Zhao, Jiatao Lou, Lin Wang   +11 more
wiley   +1 more source

In silico screening for novel inhibitors of DNA polymerase III alpha subunit of Mycobacterium tuberculosis (MtbDnaE2, H37Rv). [PDF]

PLoS ONE, 2015
Tuberculosis, a pandemic disease is caused by Mycobacterium tuberculosis (Mtb). DNA polymerase III encoded by DnaE2 of Mtb is specifically required for its survival in vivo, and hence can be considered to be a potential drug target.
Alka Jadaun, Raja Sudhakar D, N Subbarao, Aparna Dixit   +3 more
doaj   +1 more source

Influence of the Nature of the Cationic Residues on the Activity of the Antimicrobial Peptides of the Lynronne Family

Journal of Peptide Science, Volume 32, Issue 12, December 2026.
Derivatives of Lynronnes with cationic residues substitution were designed and tested in terms of antimicrobial activity, anti‐biofilm activity, mechanism of action, and in vitro toxicity. Lys‐substitution emerges as a promising strategy for improved activity and selectivity, particularly against E. coli. ABSTRACT Most antimicrobial peptides (AMPs) are
Alexis Reinbold, Maxime Gâchon, Jean‐François Cavalier, Laure Genet, Sophie Guillier, Mathilde Lescat, Muriel Serradeil‐Albalat, Linda B. Oyama, Cendrine Nicoletti, Sharon A. Huws, Nicolas Vidal, Fabiano Cavalcanti Fernandes, Andreia Gomes Martins, Stéphane Canaan, Octávio Luiz Franco, Sophie Tronnet, Olga Iranzo, Marc Maresca   +17 more
wiley   +1 more source

Predictive Power of In Silico Approach to Evaluate Chemicals against M. tuberculosis: A Systematic Review

Pharmaceuticals, 2019
Mycobacterium tuberculosis (Mtb) is an endemic bacterium worldwide that causes tuberculosis (TB) and involves long-term treatment that is not always effective.
Giulia Oliveira Timo, Rodrigo Souza Silva Valle dos Reis, Adriana Françozo de Melo, Thales Viana Labourdette Costa, Pérola de Oliveira Magalhães, Mauricio Homem-de-Mello   +5 more
doaj   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Human immunodeficiency virus increases the risk of tuberculosis due to recent re-infection in individuals with latent infection. [PDF]

, 2010
BACKGROUND: Human immunodeficiency virus associated tuberculosis (TB) disease can follow reactivation of latent Mycobacterium tuberculosis infection or recent (re-)infection with M. tuberculosis. If contemporary TB cases share identical M.
Fine, P.E.M., Glynn, J.R., Mallard, K., Sichali, L., Crampin, A.C., Mallard, K, French, N, Houben, RMGJ, Malema, S, Glynn, JR, Sichali, L, Houben, R.M.G.J, Malema, S., Crampin, AC, Fine, PEM, French, N.   +15 more
core   +4 more sources

A Case Report of Silico-Tuberculosis

Ethiopian Medical Journal
No ...
Gebrehiwot, Kibrom G., Gebremariam, Tewodros H.   +1 more
openaire   +2 more sources

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3716-3732, November 2026.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source